Michael B Atkins (Michael Atkins)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 58

Top Topics

Tyrosine Kinase

Top Venues

Journal for immunotherapy of cancer

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Neil J Shah, Alexandra Della Pia, Tianmin Wu, Aquino Williams, Melinda Weber, Brittany Sinclaire, Elli Gourna Paleoudis, Adil Alaoui, Shaked Lev-Ari, Shari Adams, Jordan Kaufman, Sahil B Parikh, Emily Tonti, Eric Muller, Michael Serzan, Divya Cheruku, Albert Lee, Aishwarya Sridhar, Benjamin Thor Perrin Hee, Jaeil Ahn, Andrew Pecora, Andrew Ip, Michael B Atkins
Clinical Outcomes of Immune Checkpoint Inhibitors in Unique Cohorts Underrepresented in Clinical Trials. Cancers 16 (12) (2024)
Charlene M Mantia, Opeyemi A Jegede, Elizabeth R Plimack, Thomas Powles, Robert J Motzer, Nizar M Tannir, Chung-Han Lee, Yoshihiko Tomita, Martin H Voss, Toni K Choueiri, Brian I Rini, Hans J Hammers, Bernard Escudier, Laurence Albigès, Lisa Rosenblatt, Michael B Atkins, Meredith M Regan, David F McDermott
Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214. Journal for immunotherapy of cancer 12 (7) (2024)
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, David F Mcdermott, Mehmet Asim Bilen, Mark Stein, Jeffrey Sosman, Robert Alter, Elizabeth R Plimack, Moshe C Ornstein, Michael Hurwitz, David J Peace, David J Einstein, Paul J Catalano, Hans Hammers, Meredith M Regan
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A). Journal for immunotherapy of cancer 12 (4) (2024)
Charlene M Mantia, Opeyemi A Jegede, Elizabeth R Plimack, Thomas Powles, Robert J Motzer, Nizar M Tannir, Chung-Han Lee, Yoshihiko Tomita, Martin H Voss, Toni K Choueiri, Brian I Rini, Hans J Hammers, Bernard Escudier, Laurence Albigès, Lisa Rosenblatt, Michael B Atkins, Meredith M Regan, David F McDermott
Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214. Journal for immunotherapy of cancer 12 (7) (2024)
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, David F Mcdermott, Mehmet Asim Bilen, Mark Stein, Jeffrey Sosman, Robert Alter, Elizabeth R Plimack, Moshe C Ornstein, Michael Hurwitz, David J Peace, David J Einstein, Paul J Catalano, Hans Hammers, Meredith M Regan
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A). Journal for immunotherapy of cancer 12 (4) (2024)
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, David F Mcdermott, Mehmet Asim Bilen, Mark Stein, Jeffrey Sosman, Robert Alter, Elizabeth R Plimack, Moshe C Ornstein, Michael Hurwitz, David J Peace, David J Einstein, Paul J Catalano, Hans Hammers, Meredith M Regan
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A). Journal for immunotherapy of cancer 12 (4) (2024)
Neil J Shah, Alexandra Della Pia, Tianmin Wu, Aquino Williams, Melinda Weber, Brittany Sinclaire, Elli Gourna Paleoudis, Adil Alaoui, Shaked Lev-Ari, Shari Adams, Jordan Kaufman, Sahil B Parikh, Emily Tonti, Eric Muller, Michael Serzan, Divya Cheruku, Albert Lee, Aishwarya Sridhar, Benjamin Thor Perrin Hee, Jaeil Ahn, Andrew Pecora, Andrew Ip, Michael B Atkins
Clinical Outcomes of Immune Checkpoint Inhibitors in Unique Cohorts Underrepresented in Clinical Trials. Cancers 16 (12) (2024)
Charlene M Mantia, Opeyemi A Jegede, Elizabeth R Plimack, Thomas Powles, Robert J Motzer, Nizar M Tannir, Chung-Han Lee, Yoshihiko Tomita, Martin H Voss, Toni K Choueiri, Brian I Rini, Hans J Hammers, Bernard Escudier, Laurence Albigès, Lisa Rosenblatt, Michael B Atkins, Meredith M Regan, David F McDermott
Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214. Journal for immunotherapy of cancer 12 (7) (2024)
Kathryn E Beckermann, Aviva G Asnis-Alibozek, Michael B Atkins, Bernard Escudier, Thomas E Hutson, Vijay Kasturi, David F McDermott, Sumanta K Pal, Camillo Porta, Brian I Rini, Elena Verzoni
Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial. The oncologist 29 (3) (2024)
Neil J Shah, Alexandra Della Pia, Tianmin Wu, Aquino Williams, Melinda Weber, Brittany Sinclaire, Elli Gourna Paleoudis, Adil Alaoui, Shaked Lev-Ari, Shari Adams, Jordan Kaufman, Sahil B Parikh, Emily Tonti, Eric Muller, Michael Serzan, Divya Cheruku, Albert Lee, Aishwarya Sridhar, Benjamin Thor Perrin Hee, Jaeil Ahn, Andrew Pecora, Andrew Ip, Michael B Atkins
Clinical Outcomes of Immune Checkpoint Inhibitors in Unique Cohorts Underrepresented in Clinical Trials. Cancers 16 (12) (2024)
Kathryn E Beckermann, Aviva G Asnis-Alibozek, Michael B Atkins, Bernard Escudier, Thomas E Hutson, Vijay Kasturi, David F McDermott, Sumanta K Pal, Camillo Porta, Brian I Rini, Elena Verzoni
Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial. The oncologist (2024)
Elaine Chang, Jiaxi Zhou, Chi Song, Haley Gittleman, Laura L Fernandes, Chana Weinstock, Michael B Atkins, Sundeep Agrawal, Rajeshwari Sridhara, Nicole J Gormley, Shenghui Tang, Daniel L Suzman, Laleh Amiri-Kordestani, Paul G Kluetz, Richard Pazdur, Brian I Rini, David F McDermott, Meredith M Regan
A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Elaine Chang, Jiaxi Zhou, Chi Song, Haley Gittleman, Laura L Fernandes, Chana Weinstock, Michael B Atkins, Sundeep Agrawal, Rajeshwari Sridhara, Nicole J Gormley, Shenghui Tang, Daniel L Suzman, Laleh Amiri-Kordestani, Paul G Kluetz, Richard Pazdur, Brian I Rini, David F McDermott, Meredith M Regan
A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (15) (2024)
Kathryn E Beckermann, Aviva G Asnis-Alibozek, Michael B Atkins, Bernard Escudier, Thomas E Hutson, Vijay Kasturi, David F McDermott, Sumanta K Pal, Camillo Porta, Brian I Rini, Elena Verzoni
Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial. The oncologist 29 (3) (2024)
Charlene M Mantia, Opeyemi A Jegede, Elizabeth R Plimack, Thomas Powles, Robert J Motzer, Nizar M Tannir, Chung-Han Lee, Yoshihiko Tomita, Martin H Voss, Toni K Choueiri, Brian I Rini, Hans J Hammers, Bernard Escudier, Laurence Albigès, Lisa Rosenblatt, Michael B Atkins, Meredith M Regan, David F McDermott
Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214. Journal for immunotherapy of cancer 12 (7) (2024)
Charlene M Mantia, Opeyemi A Jegede, Elizabeth R Plimack, Thomas Powles, Robert J Motzer, Nizar M Tannir, Chung-Han Lee, Yoshihiko Tomita, Martin H Voss, Toni K Choueiri, Brian I Rini, Hans J Hammers, Bernard Escudier, Laurence Albigès, Lisa Rosenblatt, Michael B Atkins, Meredith M Regan, David F McDermott
Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214. Journal for immunotherapy of cancer 12 (7) (2024)
Brian I Rini, James Brugarolas, Michael B Atkins
Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma. Journal for immunotherapy of cancer 11 (3) (2023)
Jarushka Naidoo, Catherine Murphy, Michael B Atkins, Julie R Brahmer, Stephane Champiat, David Feltquate, Lee M Krug, Javid Moslehi, M Catherine Pietanza, Joanne Riemer, Caroline Robert, Elad Sharon, Maria E Suarez-Almazor, Karthik Suresh, Michelle Turner, Jeffrey S Weber, Laura C Cappelli
Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology. Journal for immunotherapy of cancer 11 (3) (2023)
Gino Kim In, Jennifer R Ribeiro, Jun Yin, Joanne Xiu, Matias A Bustos, Fumito Ito, Frances E Chow, Gabriel Zada, Lindsay Hwang, April K S Salama, Soo J Park, Justin C Moser, Sourat Darabi, Evidio Domingo-Musibay, Maria L Ascierto, Kim Margolin, Jose Lutzky, Geoffrey T Gibney, Michael B Atkins, Benjamin Izar, Dave S B Hoon, Ari M VanderWalde
Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases. NPJ precision oncology 7 (1) (2023)
Thomas Denize, Opeyemi A Jagede, Sayed Matar, Nourhan El Ahmar, Destiny J West, Emily Walton, Aseman Sheshdeh Bagheri, Varunika Savla, Yasmin Nabil Laimon, Saurabh Gupta, Sai Vikram Vemula, David A Braun, Kelly P Burke, Paul J Catalano, Gordon J Freeman, Robert J Motzer, Michael B Atkins, David F McDermott, Arlene H Sharpe, Toni K Choueiri, Sabina Signoretti
PD-1 Expression on Intratumoral Regulatory T Cells is Associated with Lack of Benefit from Anti-PD-1 Therapy in Metastatic Clear Cell Renal Cell Carcinoma Patients. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Michael B Atkins, Paolo Antonio Ascierto, David Feltquate, James L Gulley, Douglas B Johnson, Nikhil I Khushalani, Jeffrey Sosman, Timonthy A Yap, Harriet M Kluger, Ryan J Sullivan, Hussein A Tawbi
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies. Journal for immunotherapy of cancer 11 (3) (2023)
Tian Zhang, Patrick M Forde, Ryan J Sullivan, Elad Sharon, Elizabeth Barksdale, Wendy Selig, Scot Ebbinghaus, Gina Fusaro, Damla Gunenc, Dena Battle, Robyn Burns, Marc S Hurlbert, Mark Stewart, Michael B Atkins
Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs. Journal for immunotherapy of cancer 11 (5) (2023)
Rana R McKay, Katharina Leucht, Wanling Xie, Opeyemi Jegede, David A Braun, Michael B Atkins, Marc-Oliver Grimm, Toni K Choueiri
A Pooled Analysis of 3 Phase II Trials of Salvage Nivolumab/Ipilimumab After Nivolumab in Renal Cell Carcinoma. The oncologist (2023)
Brian I Rini, James Brugarolas, Michael B Atkins
Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma. Journal for immunotherapy of cancer 11 (3) (2023)
Rahul Seth, Sanjiv S Agarwala, Hans Messersmith, Krishna C Alluri, Paolo Antonio Ascierto, Michael B Atkins, Kathryn Bollin, Matías Chacón, Nancy B Davis, Mark B Faries, Pauline Funchain, Jason S Gold, Samantha Guild, David E Gyorki, Varinder Kaur, Nikhil I Khushalani, Joanne M Jeter, Jennifer Leigh McQuade, Michael O Meyers, Anthony Provenzano, Caroline Robert, Mario Santinami, Amikar Sehdev, Vernon K Sondak, Gilliosa Spurrier, Umang Swami, Thach-Giao Truong, Katy K Tsai, Alexander C J van Akkooi, Jeffrey S Weber
Systemic Therapy for Melanoma: ASCO Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Michael B Atkins, Paolo Antonio Ascierto, David Feltquate, James L Gulley, Douglas B Johnson, Nikhil I Khushalani, Jeffrey Sosman, Timonthy A Yap, Harriet M Kluger, Ryan J Sullivan, Hussein A Tawbi
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies. Journal for immunotherapy of cancer 11 (3) (2023)
Joanna M Streck, Ju-Whei Lee, Angela Wangari Walter, Rachel L Rosen, Ilana F Gareen, Sheetal Mehta Kircher, Benjamin A Herman, Ruth C Carlos, Shaji K Kumar, Ingrid A Mayer, Nabil F Saba, Timothy S Fenske, Joel W Neal, Michael B Atkins, Frank Stephen Hodi, Christos E Kyriakopoulos, Clare M C Tempany-Afdhal, Tait D Shanafelt, Lynne I Wagner, Stephanie R Land, Elyse R Park, Jamie S Ostroff
Cigarette and alternative tobacco product use among adult cancer survivors enrolled in 9 ECOG-ACRIN clinical trials. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2023)
Tian Zhang, Patrick M Forde, Ryan J Sullivan, Elad Sharon, Elizabeth Barksdale, Wendy Selig, Scot Ebbinghaus, Gina Fusaro, Damla Gunenc, Dena Battle, Robyn Burns, Marc S Hurlbert, Mark Stewart, Michael B Atkins
Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs. Journal for immunotherapy of cancer 11 (5) (2023)
Vernon K Sondak, Michael B Atkins, Hans Messersmith, Anthony Provenzano, Rahul Seth, Sanjiv S Agarwala
Systemic Therapy for Melanoma: ASCO Guideline Update Q and A. JCO oncology practice (2023)
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, David F McDermott, Mehmet Asim Bilen, Mark Stein, Jeffrey A Sosman, Robert Alter, Elizabeth R Plimack, Moshe C Ornstein, Michael Hurwitz, David J Peace, Sabina Signoretti, Thomas Denize, Alessia Cimadamore, Catherine J Wu, David A Braun, David Einstein, Paul J Catalano, Hans Hammers
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B). Journal for immunotherapy of cancer 11 (3) (2023)
Tian Zhang, Patrick M Forde, Ryan J Sullivan, Elad Sharon, Elizabeth Barksdale, Wendy Selig, Scot Ebbinghaus, Gina Fusaro, Damla Gunenc, Dena Battle, Robyn Burns, Marc S Hurlbert, Mark Stewart, Michael B Atkins
Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs. Journal for immunotherapy of cancer 11 (5) (2023)
Thomas Denize, Yue Hou, Jean-Christophe Pignon, Emily Walton, Destiny J West, Gordon J Freeman, David A Braun, Catherine J Wu, Saurabh Gupta, Robert J Motzer, Michael B Atkins, David McDermott, Toni K Choueiri, Sachet A Shukla, Sabina Signoretti
Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (18) (2022)
Michael B Atkins, Sandra J Lee, Bartosz Chmielowski, Ahmad A Tarhini, Gary I Cohen, Thach-Giao Truong, Helen H Moon, Diwakar Davar, Mark Allen O'Rourke, Joseph J Stephenson, Brendan D Curti, Walter J Urba, Joanna M Brell, Pauline Funchain, Kari L Kendra, Alexandra P Ikeguchi, Anthony Jaslowski, Charles L Bane, Mark A Taylor, Madhuri Bajaj, Robert M Conry, Robert J Ellis, Theodore F Logan, Noel Laudi, Jeffrey A Sosman, David G Crockett, Andrew L Pecora, Ian J Okazaki, Sowjanya Reganti, Sunandana Chandra, Samantha Guild, Helen X Chen, Howard Z Streicher, Jedd D Wolchok, Antoni Ribas, Joanne M Jeter
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF -Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Michael B Atkins, Opeyemi A Jagede, Naomi B Haas, David F McDermott, Mehmet A Bilen, Mark N Stein, Jeffrey A Sosman, Robert Alter, Elizabeth R Plimack, Moshe C Ornstein, Michael E Hurwitz, David J Peace, Sabina Signoretti, Thomas Denize, Alessia Cimadamore, Catherine J Wu, David A Braun, David J Einstein, Paul J Catalano, Hans Hammers
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (25) (2022)
Dongyu Zhang, Neil J Shah, Michael R Cook, Matthew Blackburn, Michael T Serzan, Shailesh Advani, Arnold L Potosky, Subha Madhavan, Anas Belouali, Michael B Atkins, Dejana Braithwaite
Correction: Zhang et al. Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis. Cancers 2021, 13 , 6109. Cancers 14 (18) (2022)
Michael B Atkins, Hamzah Abu-Sbeih, Paolo Antonio Ascierto, Michael R Bishop, Daniel C Chen, Madhav Dhodapkar, Leisha A Emens, Marc S Ernstoff, Matthew J Ferris, Tim F Greten, James L Gulley, Roy S Herbst, Rachel W Humphrey, James Larkin, Kim A Margolin, Luca Mazzarella, Suresh S Ramalingam, Meredith M Regan, Brian I Rini, Mario Sznol
Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC). Journal for immunotherapy of cancer 10 (9) (2022)
Eric Jonasch, Michael B Atkins, Simon Chowdhury, Paul Mainwaring
Combination of Anti-Angiogenics and Checkpoint Inhibitors for Renal Cell Carcinoma: Is the Whole Greater Than the Sum of Its Parts? Cancers 14 (3) (2022)
Toni K Choueiri, Laurence Albiges, Michael B Atkins, Ziad Bakouny, Gennady Bratslavsky, David A Braun, Naomi B Haas, John B A G Haanen, A Ari Hakimi, Michael A S Jewett, Eric Jonasch, William G Kaelin, Payal Kapur, Chris Labaki, Bryan Lewis, David F McDermott, Sumanta K Pal, Kevin Pels, Susan Poteat, Thomas Powles, W Kimryn Rathmell, Brian I Rini, Sabina Signoretti, Nizar M Tannir, Robert G Uzzo, Hans J Hammers
From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (5) (2022)
Sourat Darabi, Andrew Elliott, David R Braxton, Jia Zeng, Kurt Hodges, Kelsey Poorman, Jeff Swensen, Basavaraja U Shanthappa, James P Hinton, Geoffrey T Gibney, Justin Moser, Thuy Phung, Michael B Atkins, Gino K In, Wolfgang Michael Korn, Burton L Eisenberg, Michael J Demeure
Transcriptional Profiling of Malignant Melanoma Reveals Novel and Potentially Targetable Gene Fusions. Cancers 14 (6) (2022)
Geoffrey Thomas Gibney, Jacob Zaemes, Shelly Shand, Neil J Shah, David Swoboda, Kellie Gardner, Arash Radfar, Vesna Petronic-Rosic, Michael J Reilly, Waddah B Al-Refaie, Suthee Rapisuwon, Michael B Atkins
PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanoma. Journal for immunotherapy of cancer 9 (10) (2022)
Meredith M Regan, Charlene M Mantia, Lillian Werner, Ahmad A Tarhini, James Larkin, F Stephen Hodi, Jedd Wolchok, Michael A Postow, Brian Stwalley, Andriy Moshyk, Corey Ritchings, Sandra Re, Wim van Dijck, David F McDermott, Michael B Atkins
Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067. Journal for immunotherapy of cancer 9 (11) (2022)
Michael B Atkins, Cristina Julian, Matthew H Secrest, Janet Lee, Ana M Abajo-Guijarro, Edward McKenna
Real-world treatment patterns and overall survival in BRAF -mutant melanoma patients treated with immunotherapy or targeted therapy. Future oncology (London, England) 18 (18) (2022)
Brian I Rini, Javid J Moslehi, Marc Bonaca, Manuela Schmidinger, Laurence Albiges, Toni K Choueiri, Robert J Motzer, Michael B Atkins, John B A G Haanen, Mariangela Mariani, Jing Wang, Subramanian Hariharan, James M G Larkin
Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (17) (2022)
Casey Quinn, Louis P Garrison, Anja K Pownell, Michael B Atkins, Gérard de Pouvourville, Kevin Harrington, Paolo Antonio Ascierto, Phil McEwan, Samuel Wagner, John Borrill, Elise Wu
Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective. Journal for immunotherapy of cancer 8 (2) (2021)
Dongyu Zhang, Neil J Shah, Michael R Cook, Matthew Blackburn, Michael T Serzan, Shailesh Advani, Arnold L Potosky, Michael B Atkins, Dejana Braithwaite
Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis. Cancers 13 (23) (2021)
Hussein A Tawbi, Peter A Forsyth, F Stephen Hodi, Christopher D Lao, Stergios J Moschos, Omid Hamid, Michael B Atkins, Karl Lewis, Reena P Thomas, John A Glaspy, Sekwon Jang, Alain P Algazi, Nikhil I Khushalani, Michael A Postow, Anna C Pavlick, Marc S Ernstoff, David A Reardon, Igor Puzanov, Ragini R Kudchadkar, Ahmad A Tarhini, Anne Sumbul, Jasmine I Rizzo, Kim A Margolin
Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204). Neuro-oncology 23 (11) (2021)
Bryan J Schneider, Jarushka Naidoo, Bianca D Santomasso, Christina Lacchetti, Sherry Adkins, Milan Anadkat, Michael B Atkins, Kelly J Brassil, Jeffrey M Caterino, Ian Chau, Marianne J Davies, Marc S Ernstoff, Leslie A Fecher, Monalisa Ghosh, Ishmael Jaiyesimi, Jennifer S R Mammen, Aung Naing, Loretta J Nastoupil, Tanyanika Phillips, Laura D Porter, Cristina A Reichner, Carole Seigel, Jung-Min Song, Alexander I Spira, Maria E Suarez-Almazor, Umang Swami, John A Thompson, Praveen Vikas, Yinghong Wang, Jeffrey S Weber, Pauline Funchain, Kathryn Bollin
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Aung Naing, Joud Hajjar, James L Gulley, Michael B Atkins, Gennaro Ciliberto, Funda Meric-Bernstam, Patrick Hwu
Strategies for improving the management of immune-related adverse events. Journal for immunotherapy of cancer 8 (2) (2021)
Meredith M Regan, Opeyemi A Jagede, Charlene M Mantia, Thomas Powles, Lillian Werner, Robert J Motzer, Nizar M Tannir, Chung-Han Lee, Yoshihiko Tomita, Martin H Voss, Elizabeth R Plimack, Toni K Choueiri, Brian I Rini, Hans J Hammers, Bernard Escudier, Laurence Albiges, Stephen Huo, Viviana Del Tejo, Brian Stwalley, Michael B Atkins, David F McDermott
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Bianca D Santomasso, Loretta J Nastoupil, Sherry Adkins, Christina Lacchetti, Bryan J Schneider, Milan Anadkat, Michael B Atkins, Kelly J Brassil, Jeffrey M Caterino, Ian Chau, Marianne J Davies, Marc S Ernstoff, Leslie A Fecher, Pauline Funchain, Ishmael Jaiyesimi, Jennifer S R Mammen, Jarushka Naidoo, Aung Naing, Tanyanika Phillips, Laura D Porter, Cristina A Reichner, Carole Seigel, Jung-Min Song, Alexander I Spira, Maria E Suarez-Almazor, Umang Swami, John A Thompson, Praveen Vikas, Yinghong Wang, Jeffrey S Weber, Kathryn Bollin, Monalisa Ghosh
Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (35) (2021)
Olivier Michielin, Michael B Atkins, Henry B Koon, Reinhard Dummer, Paolo Antonio Ascierto
Evolving impact of long-term survival results on metastatic melanoma treatment. Journal for immunotherapy of cancer 8 (2) (2021)
Samir Gupta, Anas Belouali, Neil J Shah, Michael B Atkins, Subha Madhavan
Automated Identification of Patients With Immune-Related Adverse Events From Clinical Notes Using Word Embedding and Machine Learning. JCO clinical cancer informatics 5 (2021)
Michael T Serzan, Princy N Kumar, Michael B Atkins
Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy. Journal for immunotherapy of cancer 8 (1) (2020)
Jacob Zaemes, Ali Alzeer, Kathryn Villa, Michael B Atkins
A patient with melanoma that became sensitized to immunotherapy after treatment with a CDK4/6 inhibitor. Immunotherapy 12 (12) (2020)
Leo L Tsai, Rupal S Bhatt, Meaghan F Strob, Opeyemi A Jagede, Maryellen R M Sun, David C Alsop, Paul J Catalano, David McDermott, Philip M Robson, Michael B Atkins, Ivan Pedrosa
Arterial Spin Labeled Perfusion MRI for the Evaluation of Response to Tyrosine Kinase Inhibition Therapy in Metastatic Renal Cell Carcinoma. Radiology 298 (2) (2020)
Paolo Antonio Ascierto, Bernard A Fox, Walter J Urba, Ana Carrizosa Anderson, Michael B Atkins, Ernest C Borden, Julie R Brahmer, Lisa H Butterfield, Alessandra Cesano, Daniel C Chen, Tanja D de Gruijl, Robert O Dillman, Charles G Drake, Leisha A Emens, Thomas F Gajewski, James L Gulley, F Jr Stephen Hodi, Patrick Hwu, David Kaufman, Howard L Kaufman, Michael T Lotze, Douglas G McNeel, Kim M Margolin, Francesco M Marincola, Michael J Mastrangelo, Marcela V Maus, David R Parkinson, Pedro J Romero, Paul M Sondel, Stefani Spranger, Mario Sznol, George J Weiner, Jon M Wigginton, Jeffrey S Weber
Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. Journal for immunotherapy of cancer 8 (1) (2020)
Brian I Rini, Dena Battle, Robert A Figlin, Daniel J George, Hans Hammers, Tom Hutson, Eric Jonasch, Richard W Joseph, David F McDermott, Robert J Motzer, Sumanta K Pal, Allan J Pantuck, David I Quinn, Virginia Seery, Martin H Voss, Christopher G Wood, Laura S Wood, Michael B Atkins
The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). Journal for immunotherapy of cancer 7 (1) (2019)
Dana Alsaadi, Neil J Shah, Aline Charabaty, Michael B Atkins
A case of checkpoint inhibitor-induced celiac disease. Journal for immunotherapy of cancer 7 (1) (2019)